Nov 27 (Reuters) - Boston Scientific Corp:
* LATE-BREAKING POST-MARKET STUDY DATA REINFORCE CLINICAL PROCEDURAL SUCCESS, SAFETY OF ACURATE NEO2™ AORTIC VALVE SYSTEM
* IN EUROPEAN STUDY, PRIMARY SAFETY ENDPOINT OF ALL-CAUSE MORTALITY WAS 0.8% AT 30 DAYS Source text for Eikon: Further company coverage: